- Home
- JANX vs PAXS Comparison
JANX vs PAXS Comparison
Compare JANX & PAXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JANX | PAXS |
|---|---|---|
| Founded | 2017 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.8M | 730.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | JANX | PAXS |
|---|---|---|
| Price | $13.29 | $15.69 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $57.36 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 195.0K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.72% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.12 | $12.57 |
| 52 Week High | $44.83 | $15.93 |
Technical Indicators
Market Signals| Indicator | JANX | PAXS |
|---|---|---|
| Relative Strength Index (RSI) | 36.48 | 41.78 |
| Support Level | $12.12 | $15.83 |
| Resistance Level | $14.16 | $16.09 |
| Average True Range (ATR) | 0.75 | 0.14 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 17.66 | 8.16 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.